> Detailanzeige

Kasprowicz, Nikola S.; Hepp, Philip Gm; Andergassen, Ulrich; Scholz, Christoph; Annecke, Katja; Wischnik, Arthur; Simon, Wolfgang; Forstbauer, Helmut; Augustin, Doris; Zwingers, Thomas; Harbeck, Nadia; Sommer, Harald Leo; Friese, Klaus; Kiechle, Marion; Janni, Wolfgang; Rack, Brigitte Kathrin

Prognostic impact of weight change during chemotherapy

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Prognostic impact of weight change during chemotherapy
  • Beteiligte: Kasprowicz, Nikola S.; Hepp, Philip Gm; Andergassen, Ulrich; Scholz, Christoph; Annecke, Katja; Wischnik, Arthur; Simon, Wolfgang; Forstbauer, Helmut; Augustin, Doris; Zwingers, Thomas; Harbeck, Nadia; Sommer, Harald Leo; Friese, Klaus; Kiechle, Marion; Janni, Wolfgang; Rack, Brigitte Kathrin
  • Erschienen: American Society of Clinical Oncology (ASCO), 2012
  • Erschienen in: Journal of Clinical Oncology
  • Sprache: Englisch
  • DOI: 10.1200/jco.2012.30.15_suppl.1072
  • ISSN: 0732-183X; 1527-7755
  • Schlagwörter: Cancer Research ; Oncology
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:p> 1072 </jats:p><jats:p> Background: Besides established prognostic factors such as tumor size or nodal status, individual host factors of the patient such as obesity, physical activity and diet seem to modulate the course of breast cancer (BC) as well. However, the specific impact of weight change during adjuvant chemotherapy remains unclear. The aim of this analysis was to evaluate the influence of weight change during chemotherapy on BC survival in a large, multi-center prospectively randomized trial. Methods: The ADEBAR trial compares two anthracycline based adjuvant chemotherapy regimen in patients (pts) with lymph node positive ( &gt; 3 positive) early BC: 4 x epirubicin (E) 90 mg/m<jats:sup>2</jats:sup> + cyclophosphamide (C) 600 mg/m<jats:sup>2</jats:sup> q3w followed by 4 x docetaxel 100 mg/m<jats:sup>2</jats:sup> q3w versus 6 x E 60 mg/m<jats:sup>2 </jats:sup>+ 5-FU 500 mg/m<jats:sup>2</jats:sup> d1+d8 and C 75 mg/m<jats:sup>2</jats:sup> d1-14 q4w. Weight was measured before each cycle. The weight before the 1<jats:sup>st</jats:sup> and the 6<jats:sup>th</jats:sup> cycle was assessed. Significant weight change was defined as increase or decrease of &gt; 5% of the initial weight. Overall survival (OS), disease free survival (DFS), and BC specific survival (BCSS) were assessed by Kaplan-Meier analysis. Results: In total, 1502 pts were included in the study. 1177 of them completed 6 cycles of chemotherapy. Out of the 350 pts (29.7%) who changed weight 142 pts (12.1%) lost and 208 pts (17.7 %) gained weight. There was a significant correlation between weight change and menopausal status (p&lt;0.0001), indicating that more premenopausal pts gained and postmenopausal pts lost weight. All other tumor characteristics were similarly distributed across the groups. Pts with weight change &gt; 5% showed a significantly worse outcome with respect to OS (p = 0.0028) and BCSS (p = 0.0258). A difference in DFS was not observed (p = 0.1917). The difference in OS was limited to pts who lost weight (p = 0.0008), whereas pts with weight gain have no significant different OS (p = 0.1246) in comparison to pts with constant weight. Conclusions: Our results suggest that weight loss during anthracycline-based treatment of early stage BC is associated with poorer OS. While weight normalization has shown beneficial effects in lifestyle intervention trials, patients should be advised not to lose weight during chemotherapy. </jats:p>
  • Zugangsstatus: Freier Zugang